Viking Therapeutics Q3 net loss $15.8M ($0.21/sh); cash $155M; three clinical data reads in 2023

Viking Therapeutics, Inc.

2022-Q3 EPS reported -$0.64

Net loss of $15.8M ($0.21 per share) vs $13.2M ($0.17) in Q3 2021; nine-month net loss $49.3M ($0.64) vs $42.6M ($0.55).
Cash, cash equivalents and short-term investments $155M, down from $202M at year-end 2021.
VK2809 VOYAGE Phase 2b for NASH/fibrosis enrollment to finish Q4 2022; primary endpoint data 1H 2023.
Phase 1 data for dual GLP-1/GIP agonist VK2735 expected early 2023; Phase 1b VK0214 for X-ALD data in 1H 2023.
R&D expense $12.0M in Q3 vs $10.8M a year ago; G&A $4.2M vs $2.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.